FRTX
Income statement / Annual
Last year (2023), Fresh Tracks Therapeutics, Inc.'s total revenue was $8.01 M,
an increase of 15.31% from the previous year.
In 2023, Fresh Tracks Therapeutics, Inc.'s net income was -$5.69 M.
See Fresh Tracks Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$8.01 M
|
$6.94 M
|
$404,000.00
|
$1.82 M
|
$7.92 M
|
$1.62 M
|
$13.82 M
|
$14.53 M
|
$20.95 M
|
$15.22 M
|
| Cost of Revenue |
$0.00 |
$14.04 M |
$28.23 M |
$11.22 M |
$20.21 M |
$1.44 M |
$6.48 M |
$6.29 M |
$10.93 M |
$10.82 M |
| Gross Profit |
$8.01 M |
-$7.10 M |
-$27.83 M |
-$9.39 M |
-$12.30 M |
$186,000.00 |
$7.34 M |
$8.24 M |
$10.02 M |
$4.39 M |
| Gross Profit Ratio |
1 |
-1.02 |
-68.88 |
-5.16 |
-1.55 |
0.11 |
0.53 |
0.57 |
0.48 |
0.29 |
| Research and Development
Expenses |
$3.18 M
|
$14.04 M
|
$28.23 M
|
$11.22 M
|
$20.21 M
|
$12.33 M
|
$14.39 M
|
$10.36 M
|
$11.06 M
|
$11.47 M
|
| General & Administrative
Expenses |
$11.18 M
|
$14.43 M
|
$12.42 M
|
$11.58 M
|
$12.17 M
|
$8.94 M
|
$12.81 M
|
$13.35 M
|
$19.29 M
|
$20.38 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.44 M
|
$6.48 M
|
$6.29 M
|
$10.93 M
|
$10.82 M
|
| Selling, General &
Administrative Expenses |
$11.18 M
|
$14.43 M
|
$12.42 M
|
$11.58 M
|
$12.17 M
|
$8.94 M
|
$12.81 M
|
$13.35 M
|
$19.29 M
|
$20.38 M
|
| Other Expenses |
$0.00 |
$441,000.00 |
$839,000.00 |
$0.00 |
$0.00 |
-$1.44 M |
-$6.48 M |
-$6.29 M |
-$10.93 M |
-$10.82 M |
| Operating Expenses |
$14.37 M |
$28.48 M |
$40.65 M |
$22.80 M |
$32.39 M |
$21.27 M |
$27.21 M |
$23.71 M |
$30.35 M |
$31.84 M |
| Cost And Expenses |
$14.37 M |
$28.48 M |
$40.65 M |
$22.80 M |
$32.39 M |
$21.27 M |
$27.21 M |
$23.71 M |
$30.35 M |
$31.84 M |
| Interest Income |
$0.00 |
$9,000.00 |
$69,000.00 |
$63,000.00 |
$1.94 M |
$61,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$5,000.00 |
$9,000.00 |
$69,000.00 |
$0.00 |
$2.10 M |
$1.09 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$41,000.00
|
$30,000.00
|
$22,000.00
|
$10,000.00
|
$28,000.00
|
$49,000.00
|
$793,000.00
|
$1.12 M
|
$1.16 M
|
$1.66 M
|
| EBITDA |
-$5.65 M
|
-$21.06 M
|
-$39.38 M
|
-$20.90 M
|
-$24.47 M
|
-$19.50 M
|
-$12.59 M
|
-$8.06 M
|
-$8.25 M
|
-$14.96 M
|
| EBITDA Ratio |
-0.71 |
-3.04 |
-99.61 |
-11.51 |
-3.09 |
-14.2 |
-1 |
-0.65 |
-0.4 |
-1.1 |
| Operating Income Ratio
|
-0.79
|
-3.1
|
-99.61
|
-11.51
|
-3.09
|
-12.11
|
-0.97
|
-0.63
|
-0.45
|
-1.09
|
| Total Other
Income/Expenses Net |
$666,000.00
|
$432,000.00
|
$770,000.00
|
$63,000.00
|
$591,000.00
|
$3.39 M
|
$426,000.00
|
$204,000.00
|
$166,000.00
|
$134,000.00
|
| Income Before Tax |
-$5.69 M |
-$21.10 M |
-$39.47 M |
-$20.91 M |
-$23.88 M |
-$16.25 M |
-$12.96 M |
-$8.97 M |
-$9.24 M |
-$16.49 M |
| Income Before Tax Ratio
|
-0.71
|
-3.04
|
-97.71
|
-11.48
|
-3.02
|
-10.02
|
-0.94
|
-0.62
|
-0.44
|
-1.08
|
| Income Tax Expense |
$0.00 |
-$441,000.00 |
$47,000.00 |
-$10,000.00 |
$2.07 M |
$4.48 M |
-$1.22 M |
-$1.32 M |
-$166,000.00 |
-$1.80 M |
| Net Income |
-$5.69 M |
-$20.66 M |
-$39.52 M |
-$20.90 M |
-$25.95 M |
-$16.25 M |
-$12.96 M |
-$8.97 M |
-$9.24 M |
-$16.49 M |
| Net Income Ratio |
-0.71 |
-2.98 |
-97.82 |
-11.47 |
-3.28 |
-10.02 |
-0.94 |
-0.62 |
-0.44 |
-1.08 |
| EPS |
-0.96 |
-7.36 |
-22.14 |
-38.37 |
-386.21 |
-234.41 |
-316.76 |
-282.12 |
-317.17 |
-585.11 |
| EPS Diluted |
-0.96 |
-7.36 |
-22.14 |
-38.37 |
-386.21 |
-234.41 |
-316.76 |
-282.12 |
-317.17 |
-585.11 |
| Weighted Average Shares
Out |
$5.91 M
|
$2.81 M
|
$1.78 M
|
$544,759.00
|
$67,178.00
|
$69,339.00
|
$40,914.00
|
$31,806.00
|
$29,126.00
|
$28,186.00
|
| Weighted Average Shares
Out Diluted |
$5.91 M
|
$2.81 M
|
$1.78 M
|
$544,759.00
|
$67,178.00
|
$69,339.00
|
$40,914.00
|
$31,806.00
|
$29,126.00
|
$28,186.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
